RIS profile before and after chemotherapy
| Treatment . | No. of RIS . | Range of dpt . | No. of chemotherapy treatments . |
|---|---|---|---|
| Prechemotherapy | 157 | 61-112 | |
| Temozolomide* | 73 | 80-112 | |
| BCNU† | 84 | 61-104 | |
| No. of RIS <10 kb from proto-oncogene TSS | 3 | ||
| No. of RIS <100 kb from proto-oncogene TSS | 8 | ||
| No. of RIS <500 kb from proto-oncogene TSS | 56 | ||
| Average distance from proto-oncogene TSS | ∼1.81 Mb | ||
| Postchemotherapy | 127 | 701-1448 | |
| Temozolomide* | 64 | 722-1425 | 9 (G179) and 9 (G197)‡ |
| BCNU† | 63 | 701-1448 | 2 (G069) and 4 (G154) |
| BCNU§ | 36 | 740-1037 | 7 (G187) and 4 (G250) |
| No. of RIS <10 kb from proto-oncogene TSS | 2 | ||
| No. of RIS <100 kb from proto-oncogene TSS | 6 | ||
| No. of RIS <500 kb from proto-oncogene TSS | 37 | ||
| Average distance from proto-oncogene TSS | ∼2.19 Mb | ||
| Total sites | 284 | ||
| Shared sites | 19 |
| Treatment . | No. of RIS . | Range of dpt . | No. of chemotherapy treatments . |
|---|---|---|---|
| Prechemotherapy | 157 | 61-112 | |
| Temozolomide* | 73 | 80-112 | |
| BCNU† | 84 | 61-104 | |
| No. of RIS <10 kb from proto-oncogene TSS | 3 | ||
| No. of RIS <100 kb from proto-oncogene TSS | 8 | ||
| No. of RIS <500 kb from proto-oncogene TSS | 56 | ||
| Average distance from proto-oncogene TSS | ∼1.81 Mb | ||
| Postchemotherapy | 127 | 701-1448 | |
| Temozolomide* | 64 | 722-1425 | 9 (G179) and 9 (G197)‡ |
| BCNU† | 63 | 701-1448 | 2 (G069) and 4 (G154) |
| BCNU§ | 36 | 740-1037 | 7 (G187) and 4 (G250) |
| No. of RIS <10 kb from proto-oncogene TSS | 2 | ||
| No. of RIS <100 kb from proto-oncogene TSS | 6 | ||
| No. of RIS <500 kb from proto-oncogene TSS | 37 | ||
| Average distance from proto-oncogene TSS | ∼2.19 Mb | ||
| Total sites | 284 | ||
| Shared sites | 19 |
Sites identified in dogs that were treated with O6BG and temozolomide.
Sites identified in dogs that were treated with O6BG and BCNU.
Dogs G179 and G197 received a total of 10 chemotherapy treatments, but only 9 before retrovirus integration site analysis.
Sites identified in dogs (G187 and G250) that were treated with O6BG and BCNU but not included in the analysis of total sites or postchemotherapy.